New #Stocks to watch - Biotech (NasdaqGS: $KTRA), Mining (TSX: $MKO.V), Energy (NYSE American: $INDO), eSport (CSE: $GSQ.C), Cannabis (CSE: $CBDX.C), Cleantech (NasdaqGS: $BHTG)
Point Roberts WA, Delta BC, October16, 2020 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading retail investor and trader resource, announces its weekly roundup of
stocks to watch. Today’s stocks in Biotech, Mining, Energy, eSport, Cannabis,
Cleantech, Tech and Real Estate have been added to our list of free stock
directories in each sector.
Read this in full at https://www.investorideas.com/news/2020/main/10161Stocks.asp
Investors
can trade these stocks and other ideas on our site using our list
of top stock trading apps including Robinhood, Acorn, Stash and others.
This week’s new biotech companies
are involved in biotechnologies, genetics, pharmaceutical, medical device, life
sciences, healthcare, health care and COVID-19 research.
The latest mining companies
are both listed on the TSX Venture Exchange while the latest cannabis and
gaming companies are listed on the Canadian Stock Exchange (CSE).
The newest cleantech
company is involved in waste management, including waste-to-energy and the newest
energy company operates in Indonesia.
Finally, the latest real
estate company operates in China and the latest tech company is based in India.
New Stocks added to Biotech stocks directory:
Kintara Therapeutics, Inc. (NasdaqGS:KTRA) is dedicated to the development of novel
cancer therapies for patients with unmet medical needs. Kintara is developing
two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with
reduced risk development programs. The
two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast
cancer (CMBC). VAL-083 is a "first-in-class", small-molecule
chemotherapeutic with a novel mechanism of action that has demonstrated
clinical activity against a range of cancers, including central nervous system,
ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in
U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these prior NCI-sponsored clinical studies,
Kintara is currently conducting clinical trials to support the development and
commercialization of VAL-083 in GBM. Kintara is also advancing its proprietary,
late-stage photodynamic therapy platform that holds promise as a localized
cutaneous, or visceral, tumor treatment as well as in other potential
indications. REM-001 therapy, has been previously studied in four Phase 2/3
clinical trials in patients with CMBC, who had previously received chemotherapy
and/or failed radiation therapy. With clinical efficacy to date of 80% complete
responses of CMBC evaluable lesions, and with an existing robust safety
database of approximately 1,100 patients across multiple indications, Kintara
is advancing the REM-001 CMBC program to late-stage pivotal testing.
Neubase Therapeutics, Inc. (NasdaqGS:NBSE) is accelerating the genetic revolution using a new class of
synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around
its proprietary drug scaffold to address genetic diseases at the source by
combining the highly targeted approach of traditional genetic therapies with
the broad organ distribution capabilities of small molecules. With an initial
focus on silencing disease-causing mutations in debilitating neurological,
neuromuscular and oncologic disorders, NeuBase is committed to redefining
medicine for the millions of patients with both common and rare conditions.
OncoCyte Corporation
(NYSE American:OCX) is accelerating the genetic revolution
using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies
are centered around its proprietary drug scaffold to address genetic diseases
at the source by combining the highly targeted approach of traditional genetic
therapies with the broad organ distribution capabilities of small molecules.
With an initial focus on silencing disease-causing mutations in debilitating
neurological, neuromuscular and oncologic disorders, NeuBase is committed to
redefining medicine for the millions of patients with both common and rare
conditions.is a molecular diagnostics company whose mission is to provide
actionable answers at critical decision points across the cancer care
continuum. The Company’s proprietary tests and pharmaceutical company services
aim to save lives and improve outcomes by accelerating and optimizing the
diagnosis and treatment of cancer. The Company’s tests and services present
multiple opportunities to advance cancer care while driving the growth of its
revenue. Oncocyte recently launched DetermaRx™, a treatment stratification test
that enables the identification of early-stage lung cancer patients at high
risk for recurrence post-resection, allowing them to be treated when their
cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also
developing DetermaIO™, a gene expression test that identifies patients more
likely to respond to checkpoint inhibitor immunotherapies. The Company’s
pharmaceutical company services help pharmaceutical companies to develop new
cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests.
Lineage
Cell Therapeutics, Inc.
(NYSE American:LCTX)
is a clinical-stage biotechnology company developing novel cell therapies for
unmet medical needs. Lineage’s programs are based on its robust proprietary
cell-based therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells from its
pluripotent and progenitor cell starting materials. These differentiated cells
are developed to either replace or support cells that are dysfunctional or
absent due to degenerative disease or traumatic injury or administered as a
means of helping the body mount an effective immune response to cancer.
Lineage’s clinical programs are in markets with billion dollar opportunities
and include three allogeneic ("off-the-shelf") product candidates:
(i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a
development for the treatment of dry age-related macular degeneration, a
leading cause of blindness in the developed world; (ii) OPC1, an
oligodendrocyte progenitor cell therapy in Phase 1/2a development for the
treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic
cell therapy platform for immuno-oncology and infectious disease, currently in
clinical development for the treatment of non-small cell lung cancer and in
preclinical development for additional cancers and as a vaccine against
infectious diseases, including SARS-CoV-2, the virus which causes COVID-19
Predictive Oncology Inc. (NasdaqGS:POAI) operates through three
segments (Domestic, International and other), which contain four subsidiaries;
Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies
artificial intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development of new
targeted therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
roadmap for therapy. In addition to its proprietary precision oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor™,
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. TumorGenesis, Inc. a wholly owned subsidiary specializes in media’s that
help cancer cells grow and retain their DNA/RNA and proteomic signatures
providing researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including humans. In
addition, TumorGenesis is developing a ‘biomarker discovery’ kit and service
for life science, pharmaceutical and biotech companies, and research
institutions. Its products are sold on-line as well as through a global
distributor; US Biologicals Corporation: http://www.usbio.net. Predictive
Oncology’s Skyline Medical division markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement and disposal of
waste fluid, including blood, irrigation fluid and others, within a medical
facility, through both domestic and international divisions. The company has
achieved sales in five of the seven continents through both direct sales and
distributor partners. For more information, please visit
www.Predictive-Oncology.com. Soluble Biotech is a provider of soluble and
stable formulations for proteins including vaccines, antibodies, large and
small proteins and protein complexes. The company’s services enhance the drug
development process by rapidly optimizing protein solubility and stability.
Soluble Biotech brings transformational technology to formulation development
for protein-based pharmaceutical and vaccines. In addition, our solubilization
& stability technology supports fundamental protein research at academic,
pharmaceutical and government laboratories
Greenbrook TMS NeuroHealth Centers (TSX:GTMS.TO) Operating through 125 Company-operated treatment
centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation
("TMS") therapy, an FDA-cleared, non-invasive therapy for the
treatment of Major Depressive Disorder and other mental health disorders, in
the United States. TMS therapy provides local electromagnetic stimulation to
specific brain regions known to be directly associated with mood regulation.
Greenbrook has provided more than 500,000 TMS treatments to over 14,000
patients struggling with depression.
HealthWarehouse.com, Inc. (OTC:HEWA) is America's Leading Online Pharmacy and a
pioneer in affordable healthcare. Based in Florence, Kentucky, the Company's
services are available nationwide, shipping FDA approved prescription
medication and over-the-counter products direct to patients' doors. As one of
the first National Association of Boards of Pharmacy ("NABP")
Accredited Digital Pharmacies, HealthWarehouse.com services the mission of providing
affordable healthcare and incredible patient services to help Americans in all
50 states.
Nova Leap Health Corp (TSXV:NLH.V) s an acquisitive home health care services
company operating in one of the fastest-growing industries in the U.S. &
Canada. The Company performs a vital
role within the continuum of care with an individual and family centred focus,
particularly those requiring dementia care. Nova Leap achieved the #10 Ranking
in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector.
The Company is geographically diversified with operations in 7 different U.S.
states within the New England and South- Central regions as well as Nova
Scotia, Canada.
Calmare Therapeutics (OTC:CTTC) researches, develops and commercializes chronic,
neuropathic pain devices. Our flagship medical device – the Calmare® Pain
Therapy Device (the "Calmare Device") – is the world's only
non-invasive, non-addictive modality that can successfully treat chronic,
neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance
designation on its flagship device, which grants it the exclusive right to
sell, market, research and develop the medical device in the United States and
throughout the world. The Calmare Devices are commercially sold to medical
practices and found in U.S. military hospitals, clinics and installations..
Plus Therapeutics, Inc. (NasdaqCM:PSTV) is a clinical-stage pharmaceutical company
whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s drug
development is a unique nanotechnology platform designed to reformulate,
deliver and commercialize multiple drugs targeting rare cancers and other
diseases. The platform is designed to facilitate new delivery approaches and/or
formulations of safe and effective, injectable drugs, potentially enhancing the
safety, efficacy and convenience for patients and healthcare providers.
Joint Chiropractic,The (NasdaqGS:JYNT) revolutionized access to chiropractic care
when it introduced its retail business model in 2010. Today, the company is
making quality care convenient and affordable, while eliminating the need for
insurance, for millions of patients seeking pain relief and ongoing wellness.
With more than 550 locations nationwide and over seven million patient visits
annually, The Joint Chiropractic is a key leader in the chiropractic industry
Volition RX Ltd
(NYSE American:VNRX) is a multi-national epigenetics company
developing simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the potential to not
only prolong the life of patients, but also to improve their quality of life.
The tests are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily focused on human
diagnostics but also has a subsidiary focused on animal diagnostics. Volition's
research and development activities are centered in Belgium, with additional
offices in Texas, London and Singapore, as the company focuses on bringing its
diagnostic products to market.
Newscope Capital Corporation (CSE:PHRM)
is focused on drug repurposing with artificial intelligence. The Company’s drug
repurposing artificial intelligence platform combines multilayered processes
for integrating millions of data points and performing machine learning to
discover new uses of drugs. Wholly-owned subsidiary Pharmather Inc. was founded
in 2020 with a particular focus on repurposing ketamine and psilocybin for
neurological and pain disorders. The goal is to advance the development of
panaceAI™, our drug repurposing AI platform, validate psilocybin in
pre-clinical models of stroke and traumatic brain injury, and conduct clinical
studies with ketamine for Parkinson’s disease and other disorders of the brain
and nervous system.
New stocks added to Mining stocks directory:
Goldmoney Inc. (TSX:XAU.TO) is a precious
metal focused global business. Through its ownership of various operating
subsidiaries, the company is engaged in precious metal sales to its clients,
including arranging delivery and storage of precious metals for its clients,
coin retailing, and lending. Goldmoney clients located in over 200 countries
hold over $2.8 billion in precious metal assets. The company’s operating
subsidiaries include: Goldmoney.com, SchiffGold.com and Lend & Borrow
Trust. In addition to the Company’s principal business segments, the Company
holds a significant interest in Menē Inc., which crafts pure 24-karat gold and platinum
investment jewelry that is sold by gram weight. Through these businesses and
other investment activities, Goldmoney gains long-term exposure to precious
metals.
Mako Mining (TSX:MKO.V) is a publicly
listed gold mining, development and exploration firm. The Company is developing
its high-grade San Albino gold project in Nueva Segovia, Nicaragua. Mako's
primary objective is to bring San Albino into production quickly and
efficiently, while continuing exploration of prospective targets in Nicaragua
New Stocks added to Energy stocks directory:
Indonesia
Energy Corporation (NYSE American:INDO) is a
publicly traded energy company engaged in the acquisition and development of
strategic, high growth energy projects in Indonesia. IEC's principal assets are
its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in
Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island
of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a
representative office in Danville, California
New Stocks added to eSports stocks directory:
Gamesquare Esports Inc. (CSE:GSQ.C) Formerly Magnolia Colombia Ltd. - operates an
esports agency supported by complementary media and technology to support a
cast of influencers, players and on-screen talent in the gaming sector.
New Stocks added to Cannabis stocks directory:
Canbud Distribution Corporation (CSE: CBDX) is an early stage
Canadian science and technology based vertically integrated global cannabis and
hemp cannabinoids ("CBD") clone to consumer company. The Corporation,
through its subsidiaries, holds three industrial hemp licenses for the purposes
of supplying the global market with medicinal and wellness cannabidiol and
other cannabinoid-based products on leased lands located in McKellar, Ontario,
Kettleby, Ontario and Lakefield, Ontario. Each hemp licence allows the growing
and harvesting of hemp CBD flowers for processing into CBD and other
cannabinoids extracts.
New Stocks added to Cleantech stocks directory:
BioHiTech Global (NasdaqGS: BHTG) is a technology services company focused on
providing cost-effective solutions that improve environmental outcomes. Our
technologies for waste management include the patented processing of municipal
solid waste into a valuable renewable fuel, biological disposal of food waste
on-site, and proprietary real-time data analytics tools to reduce food waste
generation. When used individually or in combination, our solutions lower the
carbon footprint associated with waste transportation and can reduce or
virtually eliminate landfill usage. In addition, we distribute a patented
technology that achieves high-level disinfection of spaces such as classrooms,
hotel or hospital rooms and other enclosed areas to combat the spread of
viruses and bacteria without the use of harsh chemicals. Our unique solutions
enable businesses, educational institutions and municipalities of all sizes to
solve everyday problems in a smarter and more cost-effective way while reducing
their impact on the environment.
New stocks added to Tech stocks directory:
Yatra Online, Inc. (Nasdaq: YTRA) is the parent company of Yatra Online Pvt.
Ltd. which is based in Gurugram, India and is India's leading Corporate Travel
services provider with 700+ Corporate customers and one of India's leading
online travel companies and operates the website Yatra.com. The company
provides information, pricing, availability, and booking facility for domestic
and international air travel, domestic and international hotel bookings,
holiday packages, buses, trains, in city activities, inter-city and
point-to-point cabs, homestays and cruises. As a leading platform of
accommodation options, Yatra provides real-time bookings for more than 108,000
hotels in India and over 1,500,000 hotels around the world.
New Stocks added to Real Estate stocks directory:
Xinyuan Real Estate (NYSE: XIN) is an NYSE-listed real estate developer and
property manager primarily in China and recently in other countries. In China,
Xinyuan develops and manages large scale, high quality real estate projects in
over ten tier one and tier two cities, including Beijing, Shanghai, Tianjin, Zhengzhou,
Jinan, Qingdao, Chengdu, Xi'an, Suzhou, Dalian, Zhuhai and Foshan. Xinyuan was
one of the first Chinese real estate developers to enter the U.S. market and
over the past few years has been active in real estate development in New York.
Xinyuan aims to provide comfortable and convenient real estate related products
and services to middle-class consumers.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a
recognized news source publishing third party news and press releases, research
and our own original financial content. We were one of the first retail
investor sites to cover renewable energy and cleantech stocks at
investorideas.com and our domain Renewableenergystocks.com. We were also one of
the most well- known and cited defense stock sites, featuring our domain
Homelanddefensestocks.com at its peak.
We follow the money for
investors as sector sentiment shifts and technology disrupts. Our mission is to
provide investor ideas with breaking news, resources, industry articles and
interviews with leading experts.
Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking
at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy and more. Investor Idea's original branded content includes the
following podcasts and columns: Crypto
Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the
sectors we cover use our news and content services to
tell their story to interested investors. Paid for content is disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media,
podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club
https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
1 comment:
Zonat 5% Eye Drop is an anti-toxin, used in the treatment of bacterial infections of the eye. It eases the side effects of the contamination by halting the further development of the causative microorganisms. It is used in the treatment of parasitic infections of the eyes. It murders the fungi that cause eye infections and consequently treats the contamination.
Post a Comment